AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 222 min read$PVLA

Goin Kathleen sold $476K of PVLA

Goin Kathleen (Chief Operating Officer) sold 4,302 shares of PALVELLA THERAPEUTICS, INC. (PVLA) at an average of $110.73 ($110.26–$112.23, $0.48M total) across 3 trades on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Goin Kathleen
Published Jun 22, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PVLA
Neutral
medium confidence
Mentioned
$PVLA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PVLANeutralLow
01

Why it matters

The COO’s open-market sale totals ~$476K across three trades at ~$110.26–$112.23/share, executed under a pre-arranged Rule 10b5-1 plan, with holdings reduced to 0 shares.

02

Market read

Traders may monitor PVLA for follow-on insider activity, but this specific disclosure is not a fundamental catalyst.

03

What to watch

The article lacks context on total holdings pre-sale, tax/portfolio needs, and whether other insiders have concurrent activity; these can dominate interpretation.

Relevance 3/10Novelty 3/10Timing: after-hours/filing day (SEC Form 4 filed 2026-06-22)

Background

The article is an SEC Form 4 insider transaction disclosure for Palvella Therapeutics, Inc. (PVLA).

Company-level read

Ticker impact

$PVLANeutralMedium confidence
Context

Palvella Therapeutics COO Goin Kathleen sold 4,302 shares in open-market transactions for about $476K, leaving 0 shares after sale.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan, and the article provides no new operational/regulatory/financial catalyst.

Market effects

Sector

No clear sector read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, a complete exit (0 shares remaining) can still be interpreted by some traders as reduced near-term conviction.

Key entities

  • equity
    PVLA

    Palvella Therapeutics, Inc.; subject of the Form 4 insider sale disclosure.

  • insider
    Goin Kathleen

    Chief Operating Officer who sold 4,302 shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PVLA insider trading history →

Related articles

OCT 28
$PVLAMedAI 8/10

FDA grants priority review to Palvella’s lymphatic malformation therapy

Palvella Therapeutics (NASDAQ:PVLA) announced FDA Priority Review for QTORIN 3.9% gel to treat microcystic lymphatic malformations, with a target action date of February 28, 2027. The application is based on positive Phase 3 SELVA study results, showing significant efficacy and a good safety profile. The therapy has received Breakthrough Therapy, Fast Track, and Orphan Drug designations. Palvella plans a potential U.S. launch in early 2027, pending approval.

investing.com3 min
OCT 28
$PVLAMedAI 8/10

Palvella Therapeutics Gets Priority Review for QTORIN Rapamycin NDA

Palvella Therapeutics (PVLA) received FDA acceptance and Priority Review for its QTORIN rapamycin NDA, targeting a February 28, 2027 decision. The NDA seeks approval to treat microcystic lymphatic malformations, a condition with no current FDA-approved therapies. Phase 3 SELVA results showed statistical significance across all efficacy endpoints. Palvella plans a potential U.S. launch in early 2027 if approved.

tradingview.com1 min
OCT 28
$PVLAMedAI 8/10

Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set

PALVELLA THERAPEUTICS, INC. (PVLA) filed an SEC Form 8-K — Other Events. Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an esti

SEC EDGAR 8-K2 min
OCT 20
$PVLAMed

Palvella at Chardan conference: rare-disease push nears launch

Palvella Therapeutics (PVLA) presented its rare-disease strategy at Chardan's conference, targeting a commercial launch in 2025. The company raised $230M in 2024, filed an NDA for QTORIN rapamycin, and expects an FDA decision by late October. Palvella is expanding its pipeline to six indications by year-end, with a focus on skin and vascular anomaly diseases. Management anticipates peak sales of $1B-$3B for its lead programs.

investing.com3 min